# Synvect

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synvect

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.synvect.com
- Total disclosed funding: $3M
- Latest round: Seed (Mar 11, 2025)
- Investors on record: 4

## About

Founded in 2022 and based in California, US, Synvect, Inc. operates as a bioengineering platform that eradicates mosquito-borne diseases. The company was founded by its CEO, Nikolay Kandul, CSO Omar Akbari, and Ravi Solanki. In September 2024, Synvect, Inc. raised venture funding from NuFund Venture Group.

Synvect offers CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing technology to sterilize male mosquitoes. The company’s primary product includes a genetically engineered mosquito that, when released into the environment, mates with wild females. These matings result in sterile eggs, leading to a reduction in the overall mosquito population.

The company plans to utilize the September 2024 funding raised to enhance its product by using CRISPR technology for mosquito control that is scalable, sustainable, and environmentally beneficial.

## Funding rounds

- Seed, Mar 11, 2025, $3M — Gates Foundation Trust, Antler, NuFund Venture Group, Redbud VC

## Investors

- Gates Foundation Trust — Seed
- Antler (https://capitalatlas.ai/funds/antler) — Seed
- NuFund Venture Group (https://capitalatlas.ai/funds/nufund-venture-group) — Seed
- Redbud VC (https://capitalatlas.ai/funds/redbud-vc) — Seed